stockholmhansa biopharma ab said monday it has submitted a draft registration statement to the us securities and exchange commission relating to a potential initial public offering of american depositary shares in the us representing hansas ordinary shares and listing on the nasdaq stock exchange hansaa swedish biopharmaceutical company that focuses on enzymes to treat and prevent rare diseasessaid the number of adss that may be offered the number of underlying ordinary shares that may be issued and the price for such instruments havent yet been determined